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Abstract
The aims of this research to prove that repeated exposure of artemisinin can cause
pfatpase6 gene mutation on Plasmodium falciparum in vitro. The research methods
usedculture In Vitro Plasmodium falciparum of strain 2300 IC50value determination
test artemisinin, artemisinin repeated exposure test (PO1, PO2, PO3 dan PO4) dose
IC50,DNA extraction, gene amplification of pfatpase6 using Polymerase Chain Reaction
(PCR) technique, electrophoresis, PCR product purification, labeling DNA from PCR
results, DNA precipitation of PCR product, application of product labeling on the
sequencing machines, analysis of the results of sequencing, and Data Analysis. The
results of PCR pfatpase6 gene amplification include region 6 – 3216 for codon 89-1031
located in exon 1 and 2 Plasmodium falciparum 2300 by using five pairs of primers.
Primer pair 1FR produce a long amplicon of 737 bp which covers of codon 89; primer
pair 2FR produce a long amplicon of 813 bp which covers of codon 263, 431; primer
pair 4FR produce a long amplicon of 700 bp which covers of codon 460, 465, 623;
primer pair 5FR produce a long amplicon of 550 bp which includes of codon 683,
769; and primer pair 6FR produce a long amplicon of 876 bp which covers of codon
898, 1031.Multialigment pfatpase6 gene Plasmodium falciparum of strains Papua 2300
point mutations are obtained in the form of transition and transversion in treatment
groups at the same nucleotide region 123, 2035, 2043, 2138 dan 2148.Conclusion of
this research Artemisinin repeated exposure can cause point mutations in pfatpase6
genes Plasmodium falciparum of strains 2300 in vitro.
Keywords: Artemisinin, Plasmodium falciparumof strain Papua 2300, pfatpase6 gene,
point mutation.
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Development of Plasmodium falciparum resistance to antimalaria drugs and decreased
efficacy of artemisinin and its derivatives cause malaria treatment to become increas-
ingly difficult [1]. This has become one of the foremost health problems in the world
because there is no new drug to substitute for artemisinin. Prevention of artemisinin
resistance should be a top priority throughout the world. Plasmodium falciparum resis-
tance to artemisinin can happen because it is influenced by a number of factors, viz.
evolution of parasites to survive drug administration and environmental changes, such
as nutrient limitation, toxic compounds and temperature that impose new selective
and trigger selection of adaptive genetic variants [2, 3]. In the former situation, there
is a change in parasite’s lifecycle through retardation of growth at the early ring stage
and mutations in certain genes [4–6].
For instance, resistance to artemisinin has been attributed to mutations in Plasmod-
ium Falciparum adenine triphosphatase 6 gene (pfatpase6) [4, 7]. Variant Pfatpase6,
e.g.L263E, E431K, A623E and S769N, have been linked to an increased 50% inhibitory
concentrations (IC50s) of artemether against Plasmodium falciparum growth in culture
[8]. Pfatpase6 variant I89T was found inisolates from Thailand [9]. Variant H243Y from
Central Africa and silent T2694A mutation from SaoTome and Principe [10]. Thirty-
three single nucleotide polymorphisms (SNPs) also were found in 39%, 29% and 7% of
P. falciparum isolates from East andWest Africa resulting in pfatpase6mutations E431K,
N569K and A630S [11]. In Iran all Plamodium falciparum isolates exposed artemisinin
(ACT) as fist line antimalarial therapy for four years contained mutations L263E and
A623E whereas 23% of those not exposed to the drug contained E431K mutation in
Sistan and Baluchistan province, so reported that 2.6% of Plasmodium falciparum iso-
lates are resistant to artesunate and all contain pfatpase6 S769N mutation [12].
Although the mechanism of falciparum resistance to artemisinin remains under
investigation Most important molecular surveillance of artemisinin resistance based
on multi genetic markers could be more informative than relying on any one particular
molecular marker [13]. it is believed that the artemisinin resistance occurs because of
mutations in pfcrt, pfmdr1, pfatpase6 and pfk13 [14, 15].
The occurrence of resistance due to exposure to artemisinin has not to date been
investigated in P.falciparum isolates of Indonesian origin. In this study, we investigated
the effects of artemisinin exposure to Indonesian chloroquine-resistant Plasmodium
falciparum strain 2300. The results of this research can be used as the basis for the
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development of malaria therapies through molecular approaches and development of
artemisinin modification by molecular modeling.
2. Materials and Methods
2.1. Materials
Plasmodium falciparum strain 2300 (chloroquine-resistant) was fromMinistry of Health
(LITBANGKES) Indonesia and artemisinin from Sigma. parasite DNA extracted using
Invitro gen Kit, five pairs of primer, Purification, precipitation of PCR product and
labelling as using Qiagen Kit, In vitro cultivation of Plasmodium falciparum
Plasmodium falciparum strain 2300 was grown in culture using the method of Trager
and Jensen (1976) [16]. The parasites were synchronized at ring stage with 5% sorbitol
treatment that selectively kill all late parasite stages. Culture were followed by stan-
dard conditions for 48 h [17]. Parasite growthwasmonitored bymeasuring parasitemia
of Giemsa-stained thin blood smears after 48 hours until proportion 5% of ring growth
[18, 19]. IC50 value (concentration required to inhibit growth by 50%) of artemisinin
against Plasmodium.falciparum strain 2300 growth in culturewas determined by adding
10−3, 10−4,10−5.10−6,10−7,10−8,10−9,10−10 M artemisinin to parasite cultures at ring stage
and monitoring parasitemia as described. Experiments were conducted in duplicate in
a 24-well microplate.
2.2. Exposure to artemisinin
For each treatment, 0.5 µl RBC (hematocrit 15%) plus 1µl of infected RBC (>5% para-
sitemia) were added to 1350 µl of culture medium containing 150 µl artemisinin corre-
sponding to IC50concentration. Control sample did not contain the drug. Parasite sus-
pensions were cultured as described above for 48 hours, washed twice with complete
medium and cultured as before. First artemisinin exposure (PO1) using IC50 values (10−8
M). If parasite viable and reaches 5% parasitemia IC50 assesment as before. Further
results newly IC50used for the second artemisinin exposure (PO2) so the same way to
third and fourth artemisinin exposure (PO3, PO4) [2, 20].
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T 1: Primers Used in The Study for Amplication of Selected Regions of Pfatpase6.











2.3. PCR amplification and sequencing of pfatpase6
Parasite DNA was isolted using a commercial kit (Invitrogen). Primers employed in
PCR amplification of sequences containing codons suspected of frequent mutations
associated with artemisinin resistance are listed in Table 1 (Imwong et al. (2010) [21].
PCR was carried out in a 20 µl mixture containing primers 1µl (F) 1µl (R), 2 µl DNA
template, 10 µl 2xPCR master mix solution. Thermocycling was performed in a Bioer
PCR instruments follows: 95∘C for 5 minutes; followed by 45 cycles of 95∘C for 30 s, 56∘C
for 30 s, this condition was used for all primer pairs and 72∘C for 30 s with a final heating
at 72∘C for 10 minutes. Amplicons were analyzed by 1% agarose. DNA marker (1kb
Ladder Inviutrogen) for confirm the size of band is correct, gel-electrophoresis contain-
ing ethidium bromide and photographed under UV illumination. Gel-purified amplicons
(using Min Elute Purification Kit, Qiagen) were sequenced using 3130 Genetic Analyser
(Applied Biosytems). Sequences were aligned results using GENETIYX Wyn Version 9
(Edit View 5 NT Software). The results of sequencing nucleotides compared with NCBI
databases using BLAST program shows pfatpase6 gene of Plasmodium falciparum 2300
strain. It was nucleotides homologous 2750 base pair of 99% with isolates sequence
ID (KC 577098.1; JN 983273.1; AB 576310.1; AL 844501.1; XM0013509581) which is Plas-
modium falciparum Serca gene (sarcoplasmic reticulum endoplasmic ATPase6 Ca2+)
3. Results
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Figure 1: The results of PCR pfatpase6 Plasmodium falciparum gene strain 2300 in the control group and
the treatment group with artemisinin exposure of IC50concentration using 5 pairs of primers. Description
A: Control, B: PO1, C: PO2, D: PO3, E: PO4, M:Marker, 1FR: Primer 1 Forward-Reverse, 2FR: Primer 2 Forward-
Reverse, 4FR: Primer 4 Forward Reverse, 5FR: Primer 5 Forward-Reverse, 6FR: Primer 6 Forward-Reverse, a:
737 bp, b: 813 bp, c:700 bp, d: 550 bp, e: 876 bp.
3.1. Artemisinin exposure on Plamodium falciparum 2300 IC50 values
IC50 values on first artemisinin exposure (PO1) 5x10−8M, second artemisinin exposure
(PO2) 7.5 × 10−7M, third artemisinin exposure (PO3) 2.5 × 10−5 M and fourth artemisinin
exposure (PO4) 5x10−4 M. Repeated artemisinin exposure influence changes in IC50
[22].
3.2. Artemisinin exposure on Plasmodium falciparum 2300
pfatpase6 sequence
Following exposure to artemisinin, five regions in Plasmodium falciparum 2300 pfat-
pase6 exons 1 and 2 were PCR amplified and sequenced. These regions contained
codons of 10 pfatpase6 amino acids, namely, I89,L263, E431,N460, N465,A623,N683,
S769, I898, and C1031, commonly mutated in artemisinin-resistant Plasmodium falci-
parum. As expected, amplicon sizes remained unchanged from artemisinin-untreated
control, despite increase in IC50values (Fig 1).
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Sequencing of the five amplicons from each of the four artemisinin-exposed Plas-
modium falciparum 2300 lines revealed no changes among these 10 pfatpase6 amino
acids from control, although there were a number of sporadic silent mutations present
in some of the artemisinin-exposed lines. Experimental model point mutations in Plas-
modium falciparum pfatpase6 gene exposed with recurring artemisinin showed a simi-
larity to nucleotide region changes (PO1, PO2, PO3 and PO4). Transition point muta-
tions in exon 1 nucleotide region 123 changes nucleotide base T - C, at exon 2 on
the nucleotide region 2035 the nucleotide bases changes G - A, nuleotida region 2148
changing bases C - T. Transversion point mutations occur in exon 2 nucleotide region
1915 and 2138 changing bases A - T (Figure 2).
4. Discussion
The results of complete DNA sequencing for pfatpase6 gene references 4.049 base
pairs (bp) located on chromosome1. The pfatpase6 gene contains three exons and two
introns. Fragments start to 1793 base pairs as the coding region of exon 1, exon 2
until 3498 base pair fragments and the remaining fragments up to 4.049 base pairs
as exons 3. The sequencing results of isolates of Plasodium falciparum strain 2300.The
region codon 69, 263, 431, 460, 465, 623, 683, 769.898, 1031, where commonmutation
always occur, was associated with Plasmodium resistant to artemisinin.
The results of the sequencing alignment analysis of the nucleotide sequence of the
gene pfatpase6 Plasmodium Falciparum of strains 2300, the control treatment group
(C) and the artemisinin repeated exposure treatment group (PO1, PO2, PO3 and PO4)
showed that the control group did not show any visible mutations in the arrangement
of nucleotide bases. The artemisinin repeated exposure treatment group on PO1, PO2,
PO3 and PO4 showed a point mutation because of there placement of one pair of
nucleotide bases that vary in length and nucleotide bases ranging from exon1 to exon
2 at pfatpase6 genes. Point mutations were in the form of transition and transversion.
Variation in the arrangement of nucleotides in the treatment group of repeated
exposure to artemisinin occur in Plasmodium falciparum of strain 2300 (PO1, PO2, PO3
and PO4). The results of this study indicate the existence of genetic diversity in exon
1 and exon 2 pfatpase6 gene. The genetic diversity of Plasmodium falciparum gener-
ate mutants with variation pattern of mutations in the diverse variable region. The
same point mutation on PO1, PO2, PO3 and PO4 nucleotide region 123, 2035, 2043,
2138 and 2148 results from this study indicate that region of the nucleotide bases
can be used as a marker of Plasmodium falciparum resistant to artemisinnin marked
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with an increase IC50 value of artemisinin, which implies a decline in the sensitivity of
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Plasmodium falciparum strains 2300 against artemisinin as indicated by the increase in
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Figure 2: Multi Alignment of Plasmodium falciparum pfatpase6 genes strains 2300 in the control group and
the artemisinin repeated exposure treatment group with IC50concentrations Note: similarity to nucleotide
region changes.
the value of IC50artemisinin, causing extra-time clearance parasites in the body and
the speed of which can cause a recurrence of severe malaria until death [22]. This is
in accordance with research conducted by Afoakwah et al. 2011 [23]. 2652 samples
collected from 35 countries conducted from 1990 - 2009 (25 Sub-Saharan Africa, 5
Asia, 3 Americans and 2 Oceania), which found 44 SNPs in pfatpase6 genes with a
mutation in some codons variations. The prevalence of these SNPs was associated
with decreased sensitivity of Plasmodium falciparum to artemisinin. Polymorphism in
87 isolates of Plasmodium falciparum from Niger also found 6 SNPs in the codon of
D537D pfatpase6 gene, namely, K561N, N569K, A630S, G639D, K716R, which were used
to test the efficacy of artemisinin monitoring [24].
Analysis of genetic diversity of pfatpase6 of 862 isolates of Plasmodium falciparum
in 19 populations from Asia, Africa, South America and Oceania were 71 SNPs identified
in the 106 nucleotide haplotypes with a specific mutation on every continent, and the
frequency was below 5%. The discovery of SNPs is high enough on the isolates of
Plasmodium, after molecular evolution analysis results did not find significant changes
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in pfatpase6 gene in all populations, so that the pfatpase6 gene is still appropriate as a
marker for monitoring artemisinin resistance against Plasmodium falciparum [25].
Mutations in amino acids may alter the conformity of the drug binding site and
could potentially lead to decreased sensitivity to artemisinin. The pfatpase6 gene is the
target of artemisin in compounds in Plasmodium falciparum. There was a relationship
between the pfatpase6 S769N substitution and improvement of artemether in vitro
IC50values in isolates from French Guiana 769 residue located in the N cytoplasmic
domain (nucleotide binding) that is close to the important conserved area are needed
for the development of the ATPase cycle, the bond and the release of calcium that can
affect the S769N mutation in a conformational change [8].
In the transgenic parasites laboratory, the changes in artemisinin sensitivity are
associated with mutations in relatively small L263E about 10-20% which gives impact
on IC50 values change, but the change in IC50 values sufferers field isolates originating
from western Cambodia, Pailin (2.3 nM) showed a decrease in parasite clearance time
compared to sufferers of WanhPha, Thailand (1.5 nM). What was found there was a
single amino acid mutation of L363E on pfatpase6. These results demonstrate that
the role of variability in the gene cannot be controlled similar to parasites transgenic
laboratory, so that IC50 values have very important clinical implications for assessing
drug resistance. This shows that pfatpase6 is a potential target for artemisinin due to
changes in the value of IC50 artemisinin against parasites associated with amino acid
changes, which were based on the model of the structure and the drug binding sites
on the receptor, so that mutations in pfatpase6 would affect the expression of the
phenotype [26].
The test of In vitro sensitivity of dihydro artemisinin on Plsmodium falciparum isolates
collected from Cameroon started 2002-2006 showed that asingle mutation was found
in the E431K pfatpase6 gene as a warning signal to perform continuous monitoring on
molecular markers andt he activity of artemisinin and its derivatives in vitro [27].
Mutations of I89T, A438D, N464, N465S, N465, E847K, in the pfatpase6 gene sam-
ples from Pailin (Cambodia West) and mutations in the pfatpase6 gene of I89T, H243Y,
L263E, A438D, N465S samples of WangPha (Thailand) showed that there is no clear
pattern in the gene that causes resistance to artemisinin [21].
On the Pfatpase6 gene mutation found in isolates of Plasmodium falciparum isolates
from Vietnam with 8 mutations (four non synonymous I89T, N463S, N465S and
N683K), three synonymous (N460N, I898I and C1031C) and one double deletions
(∧463-464), there was no discovery of mutations S769N or A623E, E431K, but the
mutation of N683K were found in Cambodia that may be specific for Plasmodium
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falciparum from Southeast Asia. The presence of mutations N460N, N463S, N465S
and N683K and double deletions (∧ 463-464) led to the widening of the location of
the nine asparagines in interspecies variable region of pfatpase6 (domain-specific)
for Plasmodium species, so that these modification scan alter the adjustment of
Plasmodium that can affect sensitivity to artemisinin [28].
The same study conducted on clinical isolates in Senegal found that the combination
of two mutations E431K and A623E are indicating an increase in the IC50 value, so that
a point mutation can be used for molecular monitoring of artemisinin derivatives in
vitro continuous surveillance [8]. Artemisinin repeated exposure can cause in the form
of point mutations in the genes of transition and transversion of pfatpase6 genes in
Plasmodium falciparum strains 2300 in vitro. Change of bases at the same nucleotide
region on experiment model Plasmodium falciparum exposed recurring artemisinin in
vitro can be used as a marker of Plasmodium resistant to artemisinin. Conclusion of
this research artemisinin repeated exposure can cause point mutations in pfatpase6
genes Plasmodium falciparum of strains 2300 in vitro.
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